Zebrafish: a predictive model for assessing drug-induced toxicity

Drug Discovery Today

Volumn 13, Issue 9-10, 2008, Pages 394-401

  McGrath, Patricia ^a   Li, Chun Qi ^a  

^a Phylonix Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; BUNGAROTOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CLIOQUINOL; CLOMIPRAMINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A65; DIMAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMOIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GREPAFLOXACIN; METHAMPHETAMINE; MITOXANTRONE; NEUROTOXIN; NITRILE; OXIDOPAMINE; PARAQUAT; PICROTOXIN; ROFECOXIB; ROTENONE; TERFENADINE; TETRODOTOXIN; UNINDEXED DRUG; VINYL CHLORIDE;

APOPTOSIS; ATRIOVENTRICULAR BLOCK; BLEEDING; CARDIOTOXICITY; COST BENEFIT ANALYSIS; COST CONTROL; DEVELOPMENT; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; EDEMA; ELECTROCARDIOGRAM; EMBRYOTOXICITY; ENVIRONMENTAL MONITORING; ENZYME ASSAY; EXPERIMENTAL MODEL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INOTROPISM; LIVER TOXICITY; LOCOMOTION; MICROSCOPY; MOTONEURON; NANOTECHNOLOGY; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; ORGANOGENESIS; QT INTERVAL; QT PROLONGATION; REVIEW; TERATOGENESIS; TERATOGENICITY; TORSADE DES POINTES; TOXICITY TESTING; ZEBRA FISH;

ANIMALS; DRUG TOXICITY; HEART DISEASES; LIVER DISEASES; MODELS, ANIMAL; NEUROTOXINS; TERATOGENS; TOXICITY TESTS; ZEBRAFISH;

EID: 43049176656     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.03.002     Document Type: Review

References (60)

1. Parng C., et al. Zebrafish: a preclinical model for drug screening. Assay Drug Dev. Technol. 1 (2002) 41-48
2. Parng C., et al. Zebrafish apoptosis assays for drug discovery. Methods Cell Biol. 76 (2004) 75-85
3. Parng C. In vivo zebrafish assays for toxicity testing. Curr. Opin. Drug Discov. Dev. 8 (2005) 100-106
4. Ton C., and Parng C. The use of zebrafish for assessing ototoxic and otoprotective agents. Hearing Res. 208 (2005) 79-88
5. Haldi M., et al. Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 9 (2006) 139-151
6. Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol. Lett. 127 (2002) 279-284
7. + channels. J. Pharmacol. Sci. 95 (2004) 311-319
8. Thisse C., and Zon L. Organogenesis - heart and blood formation from the zebrafish point of view. Science 295 (2002) 457-462
9. Langheinrich U., et al. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. 193 (2003) 370-382
10. Sedmera D., et al. Functional and morphological evidence for a ventricular conduction system in zebrafish and Xenopus hearts. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H1152-H1160
11. Milan D.J., et al. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 107 (2003) 1355-1358
12. Milan D.J., et al. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H269-H273
13. Ackerman M.J. The long QT syndrome: ion channel diseases of the heart. Mayo Clin. Proc. 73 (1998) 250-269
14. Anderson M.E., et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am. Heart J. 144 (2002) 769-781
15. Lawrence C.L., et al. Nonclinical proarrhythmia models: predicting Torsades de Pointes. J. Pharmacol. Toxicol. Methods 52 (2005) 46-59
16. Finlayson K.H.J., et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol. 500 (2004) 129-142
17. Wiegand C., et al. Uptake, toxicity, and effects on detoxication enzymes of atrazine and trifluoroacetate in embryos of zebrafish. Ecotoxicol. Environ. Saf. 45 (2000) 122-131
18. Carney S.A., et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin activation of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator pathway causes developmental toxicity through a CYP1A-independent mechanism in zebrafish. Mol. Pharmacol. 66 (2004) 512-521
19. Ibabe A., et al. Expression of peroxisome proliferator-activated receptors in zebrafish (Danio rerio). Histochem. Cell Biol. 118 (2002) 231-239
20. Zhang C., et al. Zebrafish: an animal model for toxicological studies. Current Protocols in Toxicology (2003), John W. Wiley & Sons, Inc. pp. 1.7.1-1.7.18
21. Daly A.K. Pharmacogenetics of the cytochromes P450. Curr. Top. Med. Chem. 4 (2004) 1733-1744
22. Bresolin T., et al. Expression of PXR, CYP3A and MDR1 genes in liver of zebrafish. Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 140 (2005) 403-407
23. Tseng H.P., et al. Constitutive and xenobiotics-induced expression of a novel CYP3A gene from zebrafish larva. Toxicol. Appl. Pharmacol. 205 (2005) 247-258
24. Li C.Q., et al. Whole zebrafish cytochrome P450 microplate assays for assessing drug metabolism and drug safety. Toxicologist 97 Suppl. (2008) 148
25. Kocarek T.A., et al. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos. 23 (1995) 415-421
26. Braunbeck T.G., et al. Hepatic steatosis in zebrafish (Brachydanio rerio) induced by long-term exposure to gamma-hexachlorocyclohexane. Ecotoxicol. Environ. Saf. 19 (1990) 355-374
27. McGrath P., et al. Assessment of compound induced heart, gastrointestinal, liver and kidney toxicity in zebrafish. Toxicologist 96 Suppl. (2007) 244
28. Murtha J.M., et al. Hematologic and serum biochemical values for zebrafish (Danio rerio). Comp. Med. 53 (2003) 37-41
29. Wysowski D.K. Adverse drug event surveillance and drug withdrawals in the United States 1969-2002. Arch. Intern. Med. 165 (2005) 1363-1369
30. Ninkovic J., and Bally-Cuif L. The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse. Methods 39 (2006) 262-274
31. O'Callaghan J.P., and Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin. Drug Saf. 4 (2005) 433-442
32. Hill A., et al. Neurodevelopmental defects in zebrafish (Danio rerio) at environmentally relevant dioxin (TCDD) concentrations. Toxicol. Sci. 76 (2003) 392-399
33. Parng C., et al. Neurotoxicity assessment using zebrafish. J. Pharmacol. Toxicol. Methods 55 (2007) 103-112
34. Parng C., et al. A zebrafish assay for identifying neuroprotectants in vivo. Neurotoxicol. Teratol. 28 (2006) 509-516
35. Legendre P. Pharmacological evidence for two types of postsynaptic glycinergic receptors on the Mauthner cell of 52-h-old zebrafish larvae. J. Neurophysiol. 77 (1997) 2400-2415
36. Ali D.W., et al. Properties of miniature glutamatergic EPSCs in neurons of the locomotor regions of the developing zebrafish. J. Neurophysiol. 83 (2000) 181-191
37. Rigo J.M., et al. Heterogeneity of postsynaptic receptor occupancy fluctuations among glycinergic inhibitory synapses in the zebrafish hindbrain. J. Physiol. 553 (2003) 819-832
38. O'Callaghan J.P. Assessment of neurotoxicity: use of glial fibrillary acidic protein as a biomarker. Biomed. Environ. Sci. 4 (1991) 197-206
39. Seoane A., et al. Degeneration and gliosis in rat retina and central nervous system following 3,3″-iminodipropionitrile exposure. Brain Res. 833 (1999) 258-271
40. Dadan I.D., et al. Temporal dynamics of degenerative and regenerative events associated with cerebral ischemia in aged rat. Gerontology 49 (2003) 356-365
41. Depino A.M., et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 18 (2003) 2731-2742
42. Nielsen A.L., and Jorgensen A.L. Structural and functional characterization of the zebrafish gene for glial fibrillary acidic protein, GFAP. Gene 310 (2003) 123-132
43. Li, C.Q. et al. Whole zebrafish GFAP microplate assays for neurotoxicity screening. J. Pharmacol. Toxicol. Methods 57 (Suppl.) (in press)
44. Williamson M.A., et al. Aryl hydrocarbon receptor expression and activity in cerebellar granule neuroblasts: implications for development and dioxin neurotoxicity. Toxicol. Sci. 83 (2005) 340-348
45. Segura Aguilar J., and Kostrzewa R.M. Neurotoxins and neurotoxic species implicated in neurodegeneration. Neurotox. Res. 6 (2004) 615-630
46. Breese G.R., et al. The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res. Brain Res. Rev. 48 (2005) 57-73
47. Rink E., and Wullimann M.F. The teleostean (zebrafish) dopaminergic system ascending to the subpallium (striatum) is located in the basal diencephalons (posterior tuberculum). Brain Res. 889 (2001) 316-330
48. Rink E., and Wullimann M.F. Connections of the ventral telencephalon and tyrosine hydroxylase distribution in the zebrafish brain (Danio rerio) lead to identification of an ascending dopaminergic system in a teleost. Brain Res. Bull. 57 (2002) 385-387
49. Charriaut-Marlangue C. Apoptosis: a target for neuroprotection. Therapie 59 (2004) 185-190
50. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol. 14 (2004) 215-222
51. Mielke S., et al. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur. J. Cancer 42 (2006) 24-30
52. Jacobs J.S., and Miller M.W. Proliferation and death of cultured fetal neocortical neurons: effects of ethanol on the dynamics of cell growth. J. Neurocytol. 30 (2001) 391-401
53. Baraban S.C., et al. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 131 (2005) 759-768
54. Marathe M., and Thomas G. Current status of animal testing in reproductive toxicology. India J. Pharmacol. 22 (1990) 192-201
55. Oberemm A. The use of a refined zebrafish embryo bioassay for the assessment of aquatic toxicity. Lab. Anim. 29 (2000) 32-40
56. Fort D.J., et al. Development of a metabolic activation system for the frog embryo teratogenesis assay: Xenopus (FETAX). Teratog. Carcinog. Mutagen. 8 (1988) 251-263
57. Spitsbergen J.M., and Kent M.L. The state of the art of the zebrafish model for toxicology and toxicologic pathology research - advantages and current limitations. Toxicol. Pathol. 31 Suppl. (2003) 62-87
58. Seng W.L., et al. Determination of LC50 and visual assessment of compound induced developmental toxicity on zebrafish body, liver, intestine and heart. Toxicologist 96 Suppl. (2007) 145
59. Collins F.S., et al. Transforming environmental health protection. Science 319 (2008) 906-907
60. Ton C., et al. Zebrafish as a model for developmental neurotoxicity testing. Birth Defects Res. (Part A) 76 (2006) 553-567